Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (13)	5/28/2003 10:46:13 AM
From: Thomas	Read Replies (1) \| Respond to of 671

Hi Tuck, Fair point. Appreciate your informative posts. The RZYM thread had almost withered to the point of being a press release thread, so I am pleased to see a forum with a broad view of the technology where Sirna is focusing its efforts and with posters "who are so wise in the ways of science." From what I can gather, Sirna has technology that relates to the stabilization and use of siRNA, derived from its work on stabilizing ribozymes. Some base technology patents are in the hands of Ribopharma and Anylam. Obviously, Sirna has a strong background in Hep C and VEGF. Are the delivery issues as difficult for siRNA as they were for ribozymes? Thanks in advance. Still would be interested if anyone has ideas about why RNAI should be so much more valuable than RZYM (to the tune of 3x plus). Not clear to me that they will go through with the rights offering to existing shareholders, given the wild ride that the stock has taken. Thoughts? Cheers, Thomas